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Abstract
 
In contrast with the low frequency of most single epitope reactive T cells in the preimmune
 
repertoire, up to 1 of 1,000 naive CD8
 
 
 
 T cells from A2
 
 
 
 individuals specifically bind fluores-
cent A2/peptide multimers incorporating the A27L analogue of the immunodominant 26–35
peptide from the melanocyte differentiation and melanoma associated antigen Melan-A. This
represents the only naive antigen-specific T cell repertoire accessible to direct analysis in hu-
mans up to date. To get insight into the molecular basis for the selection and maintenance of
such an abundant repertoire, we analyzed the functional diversity of T cells composing this rep-
ertoire ex vivo at the clonal level. Surprisingly, we found a significant proportion of multimer
 
 
 
clonotypes that failed to recognize both Melan-A analogue and parental peptides in a functional
assay but efficiently recognized peptides from proteins of self- or pathogen origin selected for
their potential functional cross-reactivity with Melan-A. Consistent with these data, multimers
incorporating some of the most frequently recognized peptides specifically stained a proportion
of naive CD8
 
 
 
 T cells similar to that observed with Melan-A multimers. Altogether these re-
sults indicate that the high frequency of Melan-A multimer
 
 
 
 T cells can be explained by the ex-
istence of largely cross-reactive subsets of naive CD8
 
 
 
 T cells displaying multiple specificities.
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Introduction
 
In recent years numerous tumor-associated antigens recog-
 
nized by tumor-reactive CD8
 
 
 
 CTLs have been identified.
Albeit some of these antigens arise as the consequence of
mutations, the majority of them is derived from nonmu-
tated self-proteins either ectopically expressed (1–3) or cell
lineage-specific (4–6). Therefore, the analysis of the func-
tional TCR repertoire specific for these self-antigens is
highly relevant for the study of immune responses to cancer.
 During T cell development in the thymus T cell toler-
ance is achieved toward antigens expressed by thymic
APC. Until recently, the thymus was regarded as the site of
tolerance induction to ubiquitously expressed proteins,
whereas it was thought that tolerance to tissue specific anti-
gens was achieved through postthymic peripheral mecha-
nisms (7) or that the immune system would simply ignore
such antigens (8). Lately, however, this simplistic notion of
central versus peripheral tolerance has been challenged by
the finding that promiscuous expression of peripheral anti-
 
gens including lineage specific antigens in the thymus
mirrors the peripheral self (9). Thus, repertoire selection
toward the majority of peripheral antigens could be
 
achieved similarly to that of the ubiquitously expressed ones.
T cell repertoire selection involves TCR-mediated rec-
ognition of self-peptides by immature thymocytes (10) and
includes both negative selection of thymocytes that recog-
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nize self-peptides with high avidity and positive selection of
the ones that recognize self-peptides with low avidity. Sur-
vival of positively selected thymocytes after maturation and
migration in the periphery will again depend on the delivery
of survival signals by self-peptide/MHC ligands (11). The
molecular factors determining the size of the preimmune
pool of individual epitope specific T cells have not yet been
fully elucidated. Whereas it is well accepted that a significant
fraction of the repertoire of T cells reactive to self-peptides
escape clonal deletion (12), both the number and the nature
of the self-peptides that shape in vivo TCR repertoire for
individual epitope-specific T cells is largely unknown.
Several lines of evidence, however, indicate that this role
is likely to be played by multiple peptides. Indeed, al-
though positive selection can, to some extent, take place in
the presence of a single selecting ligand (13), both the
number and the sequence of selecting peptides significantly
impact on the frequency of single antigen-specific selected
precursors. In fetal thymic organ cultures from mice defi-
cient in presenting self-peptides because either 
 
 
 
2m or
TAP1 deficiency and therefore unable to positively select
CD8
 
 
 
 T cells, positive selection was restored by addition of
exogenous peptides and 
 
 
 
2m. Interestingly, a diverse pep-
tide mixture was more efficient than single peptides at re-
storing CD8
 
 
 
 T cell development (14, 15). When similar
experiments were performed on F1 of TCR transgenic and
 
 
 
2m-deficient mice, it was found that several single amino
acid variants of the antigenic peptide were able to mediate
a very efficient positive selection of that particular TCR.
All of these variants were, however, either extremely
weak or negative in their ability to stimulate mature pe-
ripheral T cells (16). Positive selection of single antigen-
specific T cells is therefore not only peptide dependent, but
also highly specific. In addition, as immature thymocytes
are more sensitive to TCR stimulation than mature T cells,
the number of peptide ligands able to give weak signals al-
beit sufficient to promote positive selection is larger than
the ones able to activate mature T cells and includes TCR
antagonist peptides (16). It follows that the size of individ-
ual epitope-specific T cell repertoires in the preimmune T
cell pool may primarily be impacted by the proportion of
peptides cross-recognized by the TCR of interest and pre-
sented by thymic APCs.
The direct analysis of T cells composing antigen-specific
preimmune repertoires has thus far been prevented by their
low frequency (estimated to be 
 
 
 
1–5 
 
 
 
 10
 
 
 
5
 
 cells; refer-
ence 17). Recently, the development of fluorescent HLA/
peptide multimeric arrays (multimers, reference 18) that
specifically bind to TCR has tremendously improved our
ability to detect antigen specific T cells. However, whereas
antigen experienced T cells specific for single antigens are
often easily visualized ex vivo by staining with multimers
incorporating relevant peptides, naive antigen-specific
CD8
 
 
 
 T cells are usually present in the periphery at fre-
quencies that are below multimer detection limits (19).
In humans, one exception is represented by the reper-
toire of CD8
 
 
 
 T cells reactive to the self-differentiation an-
tigen Melan-A, which is selectively expressed by normal
 
cells of the melanocytic lineage including skin melanocytes
and by the large majority of malignant melanomas (5, 20).
Phenotypically naive Melan-A multimer
 
 
 
 T cells comprise
 
 
 
10
 
 
 
3
 
 cells of circulating CD8
 
 
 
 T cells in A2
 
 
 
 healthy do-
nors and in the majority of A2
 
 
 
 melanoma patients (21).
We have recently reported that a proportion of Melan-A
multimer
 
 
 
 T cells similar to that detected in the periphery
can also be found among CD8
 
 
 
 thymocytes indicating that
this large T cell pool is mostly generated by thymic output
of a high number of precursors and not due to the periph-
eral expansion of a few positively selected precursors (22).
The functional diversity of clonotypes composing the
repertoire of Melan-A multimer
 
 
 
 T cells ex vivo, how-
ever, has not been thus far investigated. In addition, the
molecular bases for selection and maintenance of such an
aberrantly abundant repertoire of naive antigen specific T
cells have remained elusive. To gain insights into these
questions, in this study, we have analyzed functionally a
large number of circulating Melan-A multimer
 
 
 
 T cell
clones isolated ex vivo from an A2
 
 
 
 healthy donor.
The results of this analysis revealed a large functional
heterogeneity in terms of functional avidity of antigen rec-
ognition and tumor reactivity. An unprecedented finding
was that A2/Melan-A multimers specifically stained a sig-
nificant proportion of clones whose functional avidity for
Melan-A peptides was too low to be detectable in a func-
tional CTL assay, but which were able to efficiently recog-
nize peptides from proteins of self- or pathogen origin se-
lected for their potential functional cross-reactivity with
Melan-A. Altogether, the reported data indicate that this
repertoire is contributed for by largely cross-reactive sub-
sets of T cells displaying multiple specificities and suggest
that the degree of cross-reactivity of antigen specific T cells
to the pool of peptides accessible to the immune system
(degeneracy of antigen recognition) could directly impact
on the frequency of reactive precursors.
 
Materials and Methods
 
Cells and Antigen Recognition Assay.
 
Multimer
 
 
 
 CD8
 
 
 
 T cells
(see below) were purified from PBMCs ex vivo by flow cytome-
try cell sorting and cloned by limiting dilution culture in the
presence of PHA, allogenic irradiated PBMC and hrIL-2 as de-
scribed previously (23). Clones were subsequently expanded by
periodical (3–4 wk) restimulation into microtiter plates. Antigen
recognition was assessed using chromium release assay (CTL as-
say). The A2
 
 
 
 human mutant cell line CEMx721.T2 (T2) (24) or
the melanoma cell lines Me 275 (A2
 
 
 
 Melan-A
 
 
 
) and NA8-MEL
(A2
 
 
 
 Melan-A
 
 
 
) were used as targets. Briefly, after labeling with
 
51
 
[Cr] during 1 h at 37
 
 
 
C followed by extensive washing, target
cells (1,000/well) were incubated with effector cells at the indi-
cated E/T ratio during 4 h at 37
 
 
 
C in V-bottomed microwells in
the absence or presence of the indicated synthetic peptide (1
 
 
 
M). In peptide titration experiments target cells were incubated
with effectors at an E/T ratio of 10:1 in the presence of serial di-
lutions of the indicated peptide. Chromium release was measured
in the supernatant of the cultures using a 
 
 
 
-counter. The per-
centage of specific lysis was calculated as 100
 
  
 
 (experimental-
spontaneous release)/(total-spontaneous release). 
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A2/Peptide Multimers and Flow Cytometry Immunofluorescence
Analysis.
 
PE-conjugated multimeric A2/peptide complexes
containing the Melan-A enhanced peptide analogue 26–35 A27L
(ELAGIGILTV), the influenza matrix Flu-MA 58–66 (GILG-
FVFTL), the HIV-1 Pol 476–484 (ILKEPVHGV), and the pep-
tides MSI 44–10 from prostaglandin transporter (LLAGIGTVPI),
MSI 44–25 from
 
 Pseudorabies virus 
 
(VIAGIGILAI) and MSI 44–
56 from 
 
Chlamydia trachomatis 
 
(MLSGIGIFFI) were synthesized as
described previously (18, 25). Because of their lower binding ca-
pacity to A2, multimers containing Melan-A parental peptides
26–35 (EAAGIGILTV) and 27–35 (AAGIGILTV) were synthe-
sized using A2 molecules incorporating an unpaired cysteine resi-
due at the COOH terminus, that allows site-specific biotinylation
at 4
 
 
 
C (26). Samples were stained with multimers at the indicated
dose in PBS containing 0.2% BSA during 1 h at room tempera-
ture, washed once in the same buffer, stained with mAbs where
indicated during 30 min at 4
 
 
 
C, washed again, and analyzed by
flow cytometry. Anti-CD8 (SK1) and anti-CD45RA mAbs were
purchased from Becton Dickinson. The anti-CCR7 mAb 3D12
was provided by M. Lipp (Max-Dellbrueck Center for Molecular
Medicine, Berlin, Germany). Inhibition of A2/Melan-A multi-
mer staining by anti-CD8 Abs was assessed by coincubating
clones with A2/Melan-A multimers at the following doses (2/
7B12 1 
 
 
 
g/ml, 2/5F1 0.6 
 
 
 
g/ml, 2/7A11 2 
 
 
 
g/ml) resulting in
a mean staining intensity of 
 
 
 
200, together with serial dilutions
of the anti-CD8 mAb RPA-T8 (Becton Dickinson) during 1 h at
room temperature. Data analysis was performed using CELL-
Quest™ software.
 
Results
 
The Functional Repertoire of Ex Vivo Sorted A2/Melan-A
Multimer
 
 
 
 CD8
 
 
 
 T Cell Clones in an A2
 
 
 
 Healthy Donor.
 
Consistent with what we have previously reported for
other A2 expressing individuals (21, 27), 
 
 
 
10
 
 
 
3
 
 of pheno-
typically naive circulating CD8
 
 
 
 T cells from the healthy
donor HD 421 were specifically stained by A2/Melan-A
peptide multimers incorporating the peptide analogue
Melan-A 26–35 A27L (A2/Melan-A multimers thereafter,
Fig. 1). To dissect the functional heterogeneity of this rep-
ertoire we derived, by limiting dilution cloning of ex vivo
flow cytometry sorted A2/Melan-A multimer
 
 
 
 
 
CD8
 
 
 
 T
cells, 37 clones that were specifically stained by A2/Melan-A
multimers
 
 
 
as compared to background staining obtained
on CD8
 
 
 
 T cell clones of unrelated specificity (mean fluo-
rescence 
 
 
 
10, Fig. 3 A and data not shown). All A2/
Melan-A multimer
 
 
 
 
 
CD8
 
 
 
 T cells clones, however, failed
 
to be significantly stained (mean fluorescence 
 
 
 
10) with a
similar dose of multimers incorporating an unrelated HLA-
A2 binder peptide (Flu-MA 58–66) that very brightly
stained, at that dose, a Flu-MA–specific clone (mean fluo-
rescence 665, unpublished data).
 The clones exhibited a diverse BV usage, but a more re-
stricted AV usage (most clones used AV 2, Fig. 2) suggest-
ing some level of TCR structural conservation. All popula-
tions analyzed were clonally distinct as clones expressing
the same AV and BV segments had different CDR3 re-
gions (unpublished data). Avidity and fine specificity of an-
tigen recognition was assessed by titrating Melan-A paren-
tal and analogue peptides in a functional CTL assay on T2
target cells (Fig. 2 A). Tumor recognition was similarly as-
sessed on tumor cell targets expressing or not Melan-A
(Fig. 2 B). Three groups of clones were clearly distinguish-
able according to their functional activity: (1) clones that
recognized Melan-A 26–35 A27L analogue and Melan-A
parental peptides and specifically lysed Melan-A–expressing
tumor cells (e.g., clone 2/7B12) (2) clones that recognized
Melan-A 26–35 A27L analogue peptide but only very
poorly or not Melan-A parental peptides and failed to spe-
cifically lyse Melan-A–expressing tumor cells (e.g., clone
2/5F1) and (3) clones that failed to significantly recognize
Melan-A 26–35 A27L analogue peptide and Melan-A pa-
rental peptides and failed to lyse Melan-A–expressing tu-
mor cells (e.g., clone 2/7A11).
 The proportion of the different groups was of 
 
 
 
1/3 of
the total population for each group. More precisely, 12
clones (32%) fell into group 1, 15 clones (41%) into group
2 and the remaining 10 (27%) into group 3. Avidity of an-
tigen recognition clearly correlated with specific tumor ly-
sis particularly in the case of the Melan-A nonapeptide
27–35 (Fig. 2 C) indicating that, as suggested by mass spectro-
metric  analysis of naturally processed Melan-A peptides
(28), this latter could be the main peptide species present
on melanoma cells. However, the correlation between
functional avidity of antigen recognition and intensity of
multimer staining was less stringent (Fig. 3 A). Whereas a
general tendency of clones displaying lower avidity (IC
50 
 
 
 
 100 nM) to stain less intensively was observed, ex-
ceptions were also found (i.e., clones 2/2C3 or 2/5B6 dis-
played an avidity at least three orders of magnitude higher
than clones 2/5G1 or 2/2C12 but a similar or lower inten-
sity of multimer staining).
Figure 1. Ex vivo detection and phenotyping of circu-
lating A2/Melan-A multimer  CD8  T cells in a healthy
donor (HD 421). PBMCs from healthy donor HD 421
were stained with anti-CD8 ECD mAb, anti-CD45RA
FITC mAbs, anti-CCR7 APC mAb, and PE-labeled A2/
peptide multimers (4.5  g/ml) containing either Melan-A
26–35 analogue A27L (A) or an irrelevant HIV peptide
(B). Dot plots are shown for CD8 versus A2/peptide
multimer staining (A and B, numbers in the up right
quadrant represent the percentage of multimer  cells
among CD8  T cells) or for CD45RA versus CCR7 staining on gated CD8  A2/Melan-A multimer  cells (C, numbers represent the percentage of
positive cells among multimer  CD8  T cells in the corresponding quadrant). 
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 In addition, among clones displaying an avidity of anti-
gen recognition 
 
 
 
10 nM, clones recognizing the antigen
with a difference in avidity of up to three orders of magni-
tude could display comparable intensity of multimer stain-
ing. These results are consistent with our recent data in the
Melan-A and in other antigenic systems indicating that the
relative efficiency of staining of tumor antigen-specific T
lymphocytes with the corresponding fluorescent A2/pep-
tide multimers can considerably vary with staining condi-
tions and does not necessarily correlate with avidity of anti-
gen recognition (29). It is of note that specific staining, for
clones belonging to the three groups and including those
 
for which peptide recognition was not detectable (i.e.,
clone 2/7A11), was obtained with multimers incorporating
Melan-A parental peptides albeit, at equivalent dose of
multimers used, the staining was less intense, specially in
the case of multimers incorporating the nonapeptide (Fig. 3
C). Thus, isolation of clones belonging to the third group
was not due to the use of multimers incorporating the
A27L analogue. For clones belonging to each of the three
groups A2/Melan-A multimer staining was completely in-
hibited by anti-CD8 Abs (Fig. 3 B).
 However, no difference in relative inhibition was seen
among the clones irrespectively of the group they belonged
to. Thus, CD8 clearly participated to the multimer bind-
ing, in agreement with what reported previously (30), but
to a similar extent for clones of the three groups. These
data clearly demonstrate that clones from group 3 were not
isolated because binding A2/Melan-A multimers
 
 
 
in a
nonantigen-specific manner. The existence of this type of
clones was not limited to HD 421 as they were also ob-
tained in the case of other HLA-A2–expressing individuals
namely another healthy donor (HD 009) and a melanoma
patient (LAU 337, Table II). In the case of HD 009 we ob-
tained results qualitatively similar to those described for
HD 421. At variance with the latter, however, a higher
proportion of clones was found in group 2 (67%) than in
group 1 (11%) or group 3 (22%).
 As reported previously (31), Melan-A multimer
 
 
 
 CD8
 
 
 
T cells from melanoma patient LAU 337 (present among
circulating CD8
 
 
 
 T cells at a frequency of 0.1%) exhibited a
mixed phenotype composed of both CD45RA
 
bright
 
 and
CD45RA
 
low
 
 cells at roughly equivalent proportions. This
mixed phenotype is found in 
 
 
 
30% of melanoma patients,
most likely as a consequence of a spontaneous response to
the tumor, whereas in the remaining 70% Melan-A
multimer
 
  CD8  T cells exhibit a naive phenotype simi-
larly to healthy donors. Interestingly, upon immunization
with peptide Melan-A 26–35 a highly increased frequency
of CD45RAlow Melan-A multimer  T cells (2%) was
detectable among circulating CD8  T cells. Melan-A
multimer  CD8  T cell clones were isolated by ex vivo
sorting of both preimmune and postimmune samples. Out
of a total of 13 clones obtained from the preimmune sample,
the majority (8) belonged to group 1, 2 clones to group 2,
and the remaining 3 to group 3. The increased proportion
of clones in group 1 was in good agreement with the anti-
gen experience phenotype of part of the starting population.
Also, all Melan-A multimer  T cell clones obtained from
the postimmune samples (a total of 17) fell into group 1.
A2/Melan-A Multimer  Clones that Fail to Recognize
Melan-A Peptides Are Able to Recognize Peptides from Protein
of Self- or Pathogen-Origin Selected on the Basis of Their Poten-
tial Functional Cross-reactivity with Melan-A. The molecular
basis for the inability of clones from group 3 to recognize
Melan-A peptides was investigated by testing the recog-
nition, by 18 of the 37 clones from HD 421 (including 13
clones from the third group), of a panel of 71 natural
Melan-A-related peptides selected on the basis of their po-
tential functional cross-reactivity with Melan-A. These se-
Figure 2. Functional avidity of antigen recognition, fine specificity,
and tumor-reactivity of ex vivo sorted A2/Melan-A multimer  CD8  T
cell clones. Data are shown for one representative clone per group. (A)
Clonal populations were tested for peptide recognition in chromium re-
lease assay using T2 cells as targets at a lymphocyte to target ratio of 10:1
in the presence of serial dilutions of the indicated peptide. (B) Tumor rec-
ognition was similarly assessed as the indicated lymphocyte to target cell
ratios by using as target cells tumor cell lines Me275 (A2 , Melan-A )
and NA8-MEL (A2 , Melan-A ) in the absence or in the presence of
peptide Melan-A 26–35 A27L (1  M). (C) Correlation between avidity
of antigen recognition and tumor reactivity of A2/Melan-A multimer 
clonal populations. Data obtained from the experiments illustrated in A
and B are shown for 37 A2/Melan-A multimer  clonal populations. The
nM concentration of the indicated peptide which was required to obtain
50% of maximal lysis in peptide titration experiments (IC50) are shown in
y-axis. The percent specific lysis on the Melan-A  A2  tumor line Me 275
obtained at an effector to target cell ratio of 50/1 in the absence of exog-
enously added peptide is shown in x-axis. Values  20% (bar on the X-axis)
were considered as significant. Variable   and   (AV and BV) chain re-
gion usage of each clone is indicated. Un., unknown.211 Dutoit et al.
quences were retrieved by using biometric analysis (32) of
data previously generated by screening of positional scan-
ning synthetic combinatorial peptide libraries with a
Melan-A specific clone and used to identify within proteins
contained in a public database sequences with the predicted
highest stimulatory values (reference 33, and unpublished
data). As summarized in Table I, all but one of the clones
tested recognized at least one or multiple peptides, to dif-
ferent extent. Similar results were obtained with clones
from HD 009 and LAU 337 (Table II).
It is noteworthy that clones from each group, including
the ones showing little or no peptide recognition, were
able to exert efficient lytic activity in redirected lysis exper-
iments (unpublished data). The extent of cross-reactivity
between Melan-A and related sequences was sometimes
substantial and encompassed tumor-reactive clones. For ex-
ample, the tumor-reactive clone 2/4G7 was able to recog-
nize some peptides two orders of magnitude more effi-
ciently than Melan-A parental peptides (Fig. 4 A). In
addition, Melan-A multimer  clones that failed to recog-
nize Melan-A parental peptides could recognize some
Melan-A–related peptides with relatively good efficiency
(i.e., clone 2/7A11 Fig. 4 A).
Interestingly, some peptides (i.e., peptides MSI 44–10
from prostaglandin transporter, MSI 44–25 from Pseudorabies
virus or MSI 44–56 from Chlamydia trachomatis) were recog-
nized by the majority of the clones. Cross-reactivity was also
clear in terms of multimer staining: indeed, A2/peptide
multimers incorporating some among the most frequently
recognized Melan-A–related peptides were able to specifi-
cally stain both clone 2/4G7 and clone 2/7A11 (Fig. 4 B).
Because of the degenerate recognition of some of the natu-
ral Melan-A–related peptides by the majority of the Melan-A
multimer  clones and because of the ability of A2/pep-
tide multimers incorporating those peptides to cross-stain
Melan-A multimer  clones belonging to different groups,
we speculated that a significant proportion of circulating
Melan-A multimer  CD8  T cells might be cross-stained
by multimers incorporating natural Melan-A-related pep-
tides. In agreement with this hypothesis, A2/MSI 44–56
multimers specifically stained a frequency of circulating na-
ive CD8  T cells from HD 421 similar to that stained by
Melan-A multimers (Fig. 5). Similar results were obtained
with multimers incorporating other frequently recognized
peptides (i.e., MSI 44–10, MSI 44–25) albeit the proportion
of the multimer  population varied depending on both the
peptide and the dose of multimer used (unpublished data).
Discussion
This study represents the first functional dissection of a
normal self-antigen specific naive CD8  T cell repertoire.
Because of the nature of the antigen under study the results
of this analysis are relevant for the understanding of im-
mune responses to tumors in humans. Ex vivo isolated
Melan-A multimer  T cell clones displayed a large hetero-
geneity in terms of avidity of antigen recognition and tu-
mor reactivity. Tumor-reactive clones (that represented a
minority of the total population) were among the ones dis-
playing higher avidity of recognition of Melan-A parental
peptides. The latter, however, was generally low (in the
group of highly tumor reactive clones, average IC50 at  1
nM for Melan-A 27–35) as compared with CTL specific for
virally derived antigens (IC50 often in the pM range).
Clones that recognized the parental peptides with lower
avidity generally failed to significantly recognize antigen-
expressing tumor cells. These data are consistent with the
idea of the T cell repertoire specific for this self-antigen be-
ing a residual repertoire, the large majority of high avidity
self-reactive T cells being most likely deleted in the thymus.
A surprising and unprecedented finding was that a signif-
icant proportion of ex vivo sorted Melan-A multimer  T
cell clones failed to significantly recognize the antigenic
peptides. However, because of the ability of multimers to
bind T cells bearing specific TCR irrespectively of their
function, dissociation between multimer staining and T cell
Figure 3. A2/Melan-A multimer staining of clonal pop-
ulations. (A) Correlation between avidity of antigen recog-
nition and efficiency of A2/Melan-A multimer staining.
Data are shown for all A2/Melan-A multimer  clonal
populations. The mean fluorescence staining obtained by
simultaneously staining the 37 clonal populations during
1 h at room temperature with 4.5  g/ml of A2/Melan-A
multimers is shown on the x-axis. The bar on this axis rep-
resents the mean fluorescence staining obtained under the
same conditions for a clone of unrelated specificity (clone
MN/55-Flu specific for Influenza matrix peptide 58–66).
The nM concentration of peptide Melan-A 26–35 A27L
required to obtain 50% maximal lysis in peptide titration
experiments (IC50) is shown in the y-axis. (B) Inhibition
of A2/Melan-A multimer staining by anti-CD8 antibodies.
Representative clones from each group were stained with
A2/Melan-A multimers in the presence of serial dilutions
of the anti-CD8 mAb. Results are shown as percentage of
maximal staining intensity. (C) Cross-staining of A2/
Melan-A multimer  populations by multimers incorporat-
ing Melan-A parental peptides. Staining obtained upon incubation during 1 h at room temperature with serial dilutions of the indicated multimer is
shown for one representative clone per group (as in Fig. 2) and for the control clone MN/55-Flu.212 Ex Vivo Functional Repertoire of A2/Melan-A Multimer  Naive CD8  T Cells
Table I. Recognition of Natural Melan-A–related Sequences by A2/Melan-A Multimer  CD8  T Cell Clones from HD 421 
Group 1 Group 2 Group 3
Peptide 
code Species Protein Sequence 2/4A12 2/7B12 2/4G7 2/5F1  2/3A4 2/7E8 2/3B3 2/7A11 2/4G9 2/6F7 2/2G11 2/5B9 2/6C9 10D4 2/2C12 2/5B8 2/5D12 2/2H11
 nb 
positiveb
Human
MSI 44
-1 Homo sapiens KIAA0935  RVTDEAGHPV                          1
-2 Homo sapiens MRP3 NVADIGLHDV                          1
-5 Homo sapiens
SLC1A1 or 
EAAT3 or EAAC1 VLTGLAIHSI  b                         2
-9 Homo sapiens P47 RISDIRLFIV                                           6
-10 Homo sapiens
Prostaglandin 
transporter LLAGIGTVPI                                                        10
-11 Homo sapiens
ABC transporter 
MOAT-C RISDIGLADL                                3
-12 Homo sapiens KIAA0735 LISGIGIGGA        
   
                               5
-13 Homo sapiens
Hypothetical 
20 kD protein RISAIILHPN                          1
-14 Homo sapiens
Endothelin-1 
receptor  RVQGIGIPLV                          1
-15 Homo sapiens
G-protein coupled 
receptor RE2 RITDLGLSPH                             1
-17 Homo sapiens IGHG1 RLSELAIFGV                          1
-18 Homo sapiens
Monocarboxylate 
transporter 8  AVAFIGLHTS                             3
-21 Homo sapiens MRP3 NVADIGFHDV                          1
-22 Homo sapiens Melan-A/Mart-1 EAAGIGILTV                                             5
Viral 
-23
Herpes simplex 
virus Capsid protein P40 RQAGIAGHTY                          1
-24
Little cherry 
closterovirus
MT and HEL 
domains RVSNIAIATG                          2
-25
Pseudorabies 
virus Glycoprotein GIII VIAGIGILAI                                                9
-26
Pseudorabies 
virus Glycoprotein C VIAGIAILAI                          2
-27
Human 
rotavirus
Outer capsid 
protein VP4 RLSGIYGLPA                          1
-28
Human 
rotavirus
Outer capsid 
protein VP4 RMSGIYGLPA                          2
-29
Canine 
calicivirus Capsid protein NTTDIGIHVV                              3
-30 Variola virus
(XHOI-F, O, H, 
P, Q) Genes MIAGIGISLI                                                    11
-31
Bovine 
herpesvirus
type 1 Capsid protein P40 REAGIAGHTY                          2
-32
Bovine 
herpesvirus 
type 2
DNA-dependent 
DNA polymerase RLAGIGLTRA                          5
-33 Vaccinia virus Protein A49 RIADIDIKQV                             3
-35
Tobacco necrosis 
virus
RNA-directed 
RNA polymerase RYSGIGGHLL                          2
-37
Puma 
lentivirus 14 GAG polyprotein RITGICFHFG                             1
-38
Murine 
cytomegalovirus
Helicase/primase 
complex protein RLAGILDHTL                              2
-39
Human 
cytomegalovirus
Hypothetical 
protein HVLF2 RIAGLLLFQI                             1
-40 Mumps virus Fusion glycoprotein RFAGIAIGIA                             1
-41
Human 
parainfluenza 
virus 1 L protein RVRGIGIPEV                          1
-42 SINP virus
Hypothetical 
36.5 kD protein CTSIIGIFPV                                1
-45 TT virus
Hypothetical 
15.9 kD protein RAPSIGILPA                          1
-46
Human 
adenovirus 
type 12
DNA terminal
protein RQADIPLPPL                          1213 Dutoit et al.
function is predictable, and has already been documented
by us and others (29, 34, 35). Whereas in some cases the
observed dissociation was to be attributed to an inherent
inability of multimer  cells to exert effector functions (an-
ergy; reference 34), it appears that, more in general, the ef-
ficiency of multimer staining may be primarily affected by
the kinetics of TCR–ligand interaction (29, 34, 35).
Among different possibilities, we favored the hypothesis
that clones from group 3 could display some degree of
specificity for Melan-A peptides (sufficient to bind A2/
-47
Nilaparvata 
lugens 
reovirus
23.6 kD putative 
nonstructural 
protein NFAGIAILFI                             2
Bacterial 
-48
Chlorobium 
tepidum
Hypothetical 
22.8 kD protein RLSGHGIHPV                          1
-49 Bacillus subtilis YKOR RVASIGLHPS                          1
-52
Bacillus 
subtilis
Hypothetical 
48.9 kD protein LLAGLAIFPA                                        2
-53
Rickettsia 
prowazekii
Cell division protein 
FTSK homolog RLSLIGLFPI                              1
-54
Propionigenium 
modestum
ATP synthase 
beta chain RIASLGIYPA                             1
-55
Aeromonas 
salmonicida EPSP synthase RVTGIGKHSI                          2
-56
Chlamydia 
trachomatis
Arginine/ornithine 
antiporter MLSGIGIFFI                                                          11
-57
Nostoc 
punctiforme
Carboxyl terminal 
protease TRANIAIHPV                          1
-58
Streptomyces 
coelicolor
Putative secreted 
protein VLSSIGIFPI                                              8
-60
Synechococcus 
sp. REPA RVTGIGLLTG                          1
-62
Bacillus
pumilus
Anthranilate synthase 
component I LVAGIAIGPF                             1
-63
Salmonella 
typhimurium LTKB homolog RIADIPIFII                          1
-64
Burkholderia 
cepacia
Hypothetical 
23.3 kD protein SIADIAIYPW                               3
-65
Aquifex 
geolicus
ATP synthase 
beta chain RLAELGIYPA                          1
-68 E. coli
ATP-dependent 
protease LA VIADLDIHPV                          1
-69
Azospirillum 
brasiliense
Glutamate synthase 
(NADPH) large 
chain RISGIGLNGI                          2
-70
Rhizobium 
meliloti RHSC protein  LIAGHGIHPC                             2
-71 Rhizobium sp.
Y4FN probable 
ABC transporter 
permease RSAFIGIDPA                                           4
-72 E. coli
K( )/H( ) 
antiporter LLAGIAIGPW                                          4
aNumber of clones recognizing the indicated peptide.
bPeptide recognition was assessed in a CTL assay in the presence of 1 mM of the indicated peptide.     10% specific lysis,      20% specific lysis,       40% specific lysis,        60% specific lysis.
Table I. Recognition of Natural Melan-A–related Sequences by A2/Melan-A Multimer  CD8  T Cell Clones from HD 421 (Continued)
Table II. Recognition of Natural Melan-A-related Sequences by A2/Melan-A Multimer+ CD8+ T Cell Clones from HD 009 and LAU 337
HD 009 LAU 337 preimmune sample LAU 337 postimmune sample
Group 1
(2 clones)
Group 2
(12 clones)
Group 3
(4 clones)
Group 1
(8 clones)
Group 2
(2 clones)
Group 3
(3 clones)
Group 1
(17 clones)
Clone 18 10 17 3F8 1E2 3D31 2A5 1B5 2A9
MSI 44 peptides
Human 1 5 0 2 0 1 8 5 0
Viral 2 3 1 5 2 0 19 19 1
Bacterial 8 2 2 4 2 5 14 9 0
Total 11 10 3 11 4 6 41 33 1214 Ex Vivo Functional Repertoire of A2/Melan-A Multimer  Naive CD8  T Cells
Melan-A multimers) but a functional avidity too low to be
detectable in a functional assay.
This type of T cells could have been undetected in pre-
vious studies as, even when using multimers, specific T
cells are generally isolated either ex vivo or in vitro from
populations that have already undergone antigen-driven se-
lection. Indeed, if such clones could well be a normal com-
ponent of any antigen specific naive repertoire, it is likely
that, because of their unresponsiveness to antigen, they
would not normally become part of the memory pool.
They could however, at least in principle, be stimulated by
cross-reactive sequences of pathogen or self-origin such as
some of the ones identified here. Thus, staining by multi-
mers could be, in some cases, highly specific but physiolog-
ically irrelevant. These considerations further underline the
need of routinely associating a complete analysis of T cell
functions to multimer staining.
In agreement with our hypothesis most Melan-A
multimer  clones, including those unable to recognize
Melan-A peptides in functional assay, efficiently recognized
several Melan-A-related peptides selected on the basis of
their potential functional cross-reactivity with Melan-A.
Reciprocally, A2/peptide multimers incorporating some of
the most frequently recognized peptides specifically stained
a proportion of naive CD8  T cells comparable to A2/
Melan-A peptide multimers. These data suggest that TCR
from the majority of clones able to recognize Melan-A-
related natural peptides could be structurally related with
those able to recognize Melan-A parental peptides. Further
support for this hypothesis issues from the finding that the
majority of these clones use several TCR BV regions but a
conserved AV region (unpublished data). Altogether, these
data indicate that, due to the degeneracy of Melan-A anti-
gen recognition, largely cross-reactive subsets of T cells dis-
playing multiple and overlapping specificities but sharing
common structural features contribute to form the abun-
dant repertoire of Melan-A multimer  CD8  T cells.
Degeneracy of antigen recognition by Melan-A–specific
T cells was reported previously (36) and proposed to be at
the origin of the high frequency of Melan-A–specific T
cells in the periphery. The proposed molecular mechanism
was molecular mimicry, i.e., CTL responses to Melan-A
might be augmented by T cell encounters with Melan-A–
like peptides derived from sources other than Melan-A and
most likely of pathogen origin. The same authors later re-
ported that several Melan-A analogs of self-origin showed
antagonistic behavior toward Melan-A (37). Based on this
observation they proposed that encounters with self-pep-
tide analogs of Melan-A may contribute to the peripheral
maintenance of these CTL, while ultimately impairing the
efficacy of antitumor T cell responses.
Both our data and their interpretation, however, are
clearly at variance with those previous reports in that (a) de-
generacy of antigen recognition of Melan-A like sequences
is larger than anticipated and encompasses clones that are
specifically stained by multimers incorporating Melan-A
peptides but fail to recognize the latter in functional assays;
and (b) the large majority of both Melan-A multimer  T
cells as well as T cells specifically stained by A2/peptide
multimers incorporating the most frequently recognized
peptides from pathogen origin are naive. Together with the
observation that the proportion of Melan-A multimer  T
cells is similar in the thymus and in the periphery these data
indicate that, although it cannot formally be excluded that
some pathogen derived peptide could stimulate in vivo spe-
cific responses cross-reactive with Melan-A, this would not
be a frequent event, and molecular mimicry would not ac-
count for the high frequency of Melan-A–specific T cells.
Also, no peripheral tolerance is observed, and Melan-A–
specific precursors can be efficiently activated both in vitro
and in vivo by stimulation with antigen.
It is likely that Melan-A–related peptides of self-origin
described here only represent a small subgroup of the exist-
Figure 4. Cross-reactivity between Melan-A and natural Melan-A–
related peptides. (A) Relative efficiency of recognition of selected natural
Melan-A–related peptides by clone 2/4G7 (group 1) and clone 2/7A11
(group 3) was assessed in chromium release assay in the presence of graded
dilutions of the indicated peptides. (B) Cross-staining of the above clones
and of clone MN/55-Flu used as an internal control by A2/peptide mul-
timers incorporating selected Melan-A–related peptides (peptide MSI 44–
10 from prostaglandin transporter, LLAGIGTVPI; MSI 44–25 from Pseu-
dorabies virus, VIAGIGILAI; or MSI 44–56 from Chlamydia trachomatis,
MLSGIGIFFI) was assessed by staining cells during 1 h at room tempera-
ture with serial dilutions of the indicated multimer.
Figure 5. Ex vivo detection and phenotyping of circulating A2/MSI
44–56 multimer  CD8  T cells in HD 421. PBMCs from healthy donor
HD 421 were stained with A2/peptide multimers containing MSI 44–56
together with other mAbs as in Fig. 1. Dot plots are shown for CD8 ver-
sus multimer staining (A) or for CD45RA versus CCR7 staining on gated
CD8  A2/Melan-A multimer  cells (B).215 Dutoit et al.
ing ones. Why, in the presence of this large array of cross-
reactive self-peptides the Melan-A multimer  T cells re-
main mostly inactive? The natural self-peptides recognized
in vitro by Melan-A multimer  T cells with an increased or
comparable efficiency than Melan-A parental peptides are
most likely not efficiently generated by intracellular pro-
cessing as their presence in the thymus would result in T
cell deletion. In contrast, cross-reactive peptides recognized
in vitro with very low to undetectable avidity could be
among the ones that positively select Melan-A multimer 
T cells in the thymus. A similar set of peptides could
be present in the periphery and provide to Melan-A
multimer  T cells activation signals that are sufficient for
their survival but not for their activation.
In conclusion, the repertoire of Melan-A multimer  T
cells would differ from any other antigen specific repertoire
only in terms of size possibly due to the high frequency of
Melan-A–related sequences in proteins (36) and therefore
to the high proportion of TCR able to interact with those
sequences. The existence of such a degenerate recognition
of Melan-A–like sequences by a significant proportion of
different but structurally related TCRs also indicates that a
large proportion of self-peptides could contribute to the
repertoire selection of Melan-A multimer  cells in the thy-
mus as well as to their maintenance in the periphery.
Both the nature and the number of Melan-A cross-
reactive sequences present on thymic APCs as well as their
role in negative and positive selection of Melan-A
multimer  cells remain to be determined. An interesting
implication of the results of this study is that the frequency
of T cells specific for a self-antigen in the naive repertoire
could be determined by the degree of structural proximity
between the antigenic peptide and the pool of self-pep-
tides accessible to the immune system. Because of the
clear implications in the study of autoimmune diseases as
well as of tumor-specific responses, this hypothesis de-
serves further investigation.
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